Advanz Pharma (OTCMKTS:CXRXF) Hits New 1-Year Low at $10.89

Advanz Pharma Corp (OTCMKTS:CXRXF)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $10.89 and last traded at $10.89, with a volume of 390 shares. The stock had previously closed at $11.59.

A number of brokerages recently commented on CXRXF. Zacks Investment Research cut Advanz Pharma from a “hold” rating to a “sell” rating in a report on Wednesday. ValuEngine raised Advanz Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.

The stock has a fifty day moving average of $14.28 and a 200 day moving average of $16.05. The company has a market capitalization of $532.63 million, a P/E ratio of 0.92 and a beta of 0.50. The company has a debt-to-equity ratio of 6.47, a quick ratio of 1.71 and a current ratio of 2.01.

Advanz Pharma (OTCMKTS:CXRXF) last announced its earnings results on Wednesday, August 7th. The company reported ($0.42) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.03. Advanz Pharma had a negative return on equity of 55.04% and a net margin of 322.43%. The company had revenue of $131.08 million for the quarter, compared to analysts’ expectations of $127.00 million. Research analysts anticipate that Advanz Pharma Corp will post -2.09 EPS for the current fiscal year.

About Advanz Pharma (OTCMKTS:CXRXF)

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Read More: What are convertible shares? 

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.